Juno Therapeutics (NASDAQ: JUNO)

On Monday morning before the market opened, shares of Juno Therapeutics (JUNO) sky rocketed on news that they were going to be bought out by Celgene Corp (CELG) for $9 billion or $87 per share.

Shares popped over 25% to $86.23 following the announcement and will likely stay in the range until the buyout is completed sometime in the first quarter.

Executive Comments

Juno’s JCAR017 treatment for non-Hodgkin lymphoma should “be a significant growth driver beyond 2020 with potential global peak sales of approximately $3 billion,” said Celgene. “Juno’s advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene’s global leadership in hematology and adds new drivers for growth beyond 2020,” said Celgene.

JUNO Technicals

(Click on image to enlarge)

Looking above at the 5-minute chart you will see that shares made a big move to the purchase price agreed upon by the two companies. Usually with buyouts, shares prices will stay at or just below the buyout price, in this case $87.

There won’t be any short term opportunities since the move has already been made but for a longer term perspective this could really help $CELG bottom line.

Company Profile

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.

Its CD19 product candidates include JCAR017 that is in Phase I/II trials for adults with relapsed or refractory (r/r) B cell aggressive non-Hodgkin lymphoma (NHL) and pediatric patients with r/r B cell acute lymphoblastic leukemia (ALL); JCAR014, which is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies; and JCAR015 that is in Phase II trials for adult patients with r/r ALL.

The company’s CD22 product candidate comprise JCAR018, which is in Phase I trial for pediatric and young adult patients with CD22-positive r/r ALL or r/r NHL. Its additional product candidates include CD171, a cell-surface adhesion molecule to treat neuroblastoma; Lewis Y for the treatment of lung cancer; JCAR023, which is in Phase I trial for patients with refractory or recurrent pediatric neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; WT-1, an intracellular protein that is in Phase I/II clinical trials to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers; and IL13ra2 for treating glioblastoma.

Juno Therapeutics, Inc. has collaboration agreements with Celgene Corporation, Fate Therapeutics, Inc., Editas Medicine, Inc., MedImmune Limited, and Memorial Sloan Kettering Cancer Center. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.